Immunogenicity and safety study of booster dose of GSK Biologicals’ IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) vaccine

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-003324-20

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

•To assess the persistence of antibodies to all vaccine antigens before the booster dose. •To assess the immune response to the study vaccines in terms of seroprotection to diphtheria, tetanus, Haemophilus influenzae type b and poliovirus types 1, 2 and 3, and in terms of vaccine response to the pertussis antigens, one month after booster vaccination. •To assess the immune response to the study vaccines in terms of antibody concentrations or titres for all antigens, one month after the booster dose.


Critère d'inclusion

  • Booster immunisation of healthy children in the second year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) diseases

Liens